cash flow

Chevron (CVX) Stock: Oil Price Doldrums, Pipeline Deal & Analysts’ Forecasts – What’s Next?

Chevron Stock Premarket: Record Output & Cash Flow Boost – Nov 3, 2025 Key Facts

Strong Q3 Earnings and Record Production Chevron’s Q3 (ended Sept. 30) report, released Oct. 31, exceeded forecasts despite lower oil prices. Adjusted EPS was $1.85, well above the ~$1.68 consensus reuters.com (it was $2.51 a year ago). Production from legacy Chevron + Hess hit a record 4.1M barrels-of-oil equivalent per day (vs. 3.4M a year prior) ts2.tech washingtonexaminer.com. Upstream profit fell (~28% YoY) due to weaker prices, but downstream (refining/chemicals) profit nearly doubled on strong margins reuters.com. Overall, Chevron generated ~$9.4–9.9B in operating cash flow (+20% YoY) reuters.com and about $4.9B free cash. The balance sheet remains strong (cash ~$7.7B,

2 November 2025

Trash to Cash: Waste Management (WM) Stock Shines on Cash Flow and Sustainability Drive

Stock Performance and Recent Trends Waste Management’s stock has been relatively steady in recent weeks, moving only modestly amid a volatile broader market. On October 27, WM shares closed around $213.77 (down just –0.4% for the day) ahead of its earnings release stockanalysis.com. In after-hours trading following the results, the stock dipped roughly 2% to about $209 as investors digested the slight revenue miss and cautious guidance update. Overall, WM’s price has fallen about 0.8% over the past week and ~1.8% in the past month tradingview.com, a mild pullback largely in line with its sector. Year-to-date, WM is up approximately 6–7% tickernerd.com – a respectable gain though

27 October 2025

Financial Analysis · Investing · Stock Market · Sustainability · Waste Management

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded (versus ~60 million on an average day) ts2.tech. Market observers noted Adaptimmune as one of

16 October 2025

Biotech · Company Analysis · Investing · NASDAQ:ADAP · NASDAQ:HTGC · Pharmaceuticals · Stock Market